eCORE
- Brain & Mind and Behaviour
- Chronic, Prevalent Diseases & Aging
- Personalized Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
- Woman & Child Health & Rare Diseases
Team
Group Leader
Xavier Montalban Gairín
Principal Investigator (PI)
Georgina Arrambide García, Álvaro Cobo Calvo, Manuel Comabella López, Carmen Espejo Ruiz, Arnau Hervera Abad, Nicolás Miguel Fissolo, Sunny Malhotra, Xavier Montalban Gairín, Jaume Sastre-Garriga, Mar Tintoré Subirana, Carmen Tur Gomez, Àngela Vidal Jordana
Researchers
Helena Ariño Rodríguez, Elisenda Anglada Clofent, María Jesús Arévalo Navinés, Joaquín Castilló Justribó, Herena Eixarch Ahufinger, Ingrid Galán Cartañá, Alexis García Serreón, Rebeca Menéndez Díaz, Andrés Miguez González, Carlos Nos Llopis, Jordi Río Izquierdo, Xavier Sibera Aresté, Ana Zabalza De Torres
PhD Students
Luca Bollo, Imame Boutitah Benyaich, René Carvajal, Llucia Coll Benajam, Delon La Puma, Elisa Marín Ordovás, Edwin Roger Meza Murillo, Luciana Midaglia Fernández, Neus Mongay Ochoa, Agustin Pappolla, Rucsanda Pinteac, Miguel Ángel Robles Sánchez, Breogán Rodríguez Acevedo, Carmen Santoyo Medina, Andreu Vilaseca Jolonch, Javier Villacieros Àlvarez
Lab Technicians
Mireia Castillo Juárez, Lucía Gutiérrez Ruiz, Gloria López Comellas
Nursing and Technical Staff
Sergio Aguilar Alegre, Irene Alarcón Giménez, Montserrat Aroca Alsina, Patricia Arrieta Perna, Jordina Beltrán Vallés, Gabriela Bravo Vera, Sergio Cabello Martínez, Gabriel L. Camiña Rodríguez, Margarida Capell Maymó, Pere Josep Carbonell Miravet, Marga Carranza Jiménez, Marta Castro de la Visitación, Júlia Comulada Ferrer, Javier Domeño Baztán, Caterina Fernández Garberí, Silvia Ferrer López, Milagros Fraga Pereira, Rafael García Mérida, Montserrat García Serqueda, Josep Graells Salvador, Alex Granda Soto, Ana Isabel Guerrero Pérez, María Gloria Henríquez Gaztañondo, Montserrat Janer Cabo, Gaizka Loyola Sanmillán, Helena Llorente Blasco, José David Márquez Parra, Nuria Martínez Royuela, Núria Martínez Sabaté, Elisabeth Morilla Castillo, Nerea Morilla Pérez, Dúnia Muñoz Valdivielso, Margarita Navarro Pérez, Oriol Nualart Mundó, Ana María Pérez Rubio, Marta Pulido Salgado, Lidia Ramos Hernández, Mireia Resina Sallés, Marta Rodríguez Barranco, Montserrat Romero Reinaldos, Julià Enric Rubio Roca, Margarita Sáez López, Samuel Sánchez Pous, Agusto César Sao Avilés, Karen Amanda Segura Davila, Andrea Serrano Mascarós, Ricard Soriano Baliarda, Cristina Ustrell Garrido, Sergio Vergara Ruíz, Cristina Vetoret Vázquez
Selected Publications
Carvajal R, Zabalza A, Carbonell-Mirabent P, Martínez-Gómez X, Esperalba J, Pappolla A, Rando A, Cobo-Calvo A, Tur C, Rodriguez M, Río J, Comabella M, Castilló J, Rodrigo-Pendás JÁ, Braga N, Mongay-Ochoa N, Guío-Sánchez C, Vidal-Jordana Á, Arrambide G, Rodríguez-Acevedo B, Midaglia L, Borras-Bermejo B, Galán I, Sastre-Garriga J, Montalban X, Otero-Romero S, Tintoré M
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With Natalizumab
JAMA Netw Open. 2024 Apr 1;7(4):e246345
DOI: 10.1001/jamanetworkopen.2024.6345
IF: 10.5
Sastre-Garriga J, Vidal-Jordana A, Toosy AT, Enzinger C, Granziera C, Frederiksen J, Ciccarelli O, Filippi M, Montalban X, Tintore M, Pareto D, Rovira À; MAGNIMS Study Group
Value of Optic Nerve MRI in Multiple Sclerosis Clinical Management: A MAGNIMS Position Paper and Future Perspectives
Neurology. 2024 Aug 13;103(3):e209677
DOI: 10.1212/WNL.0000000000209677
IF: 8.4
Pinteac R, Soriano J, Matute-Blanch C, Lizcano JM, Duarri A, Malhotra S, Eixarch H, López Comellas G, Montalban X, Comabella M
Chitinase 3-like 1 is neurotoxic in multiple sclerosis patient-derived cortical neurons.
Clin Transl Med. 2024 Dec;14(12):e70125
DOI: 10.1002/ctm2.70125
IF: 7.9
Carvajal R, Rodríguez-Acevedo B, García-Vasco L, Zabalza A, Ariño H, Bollo L, Cabello-Clotet N, Castilló J, Cobo-Calvo Á, Comabella M, Falcó-Roget A, Galán I, García-Sarreón A, Gómez-Estévez I, Granados G, La Puma D, Mato Chain G, Midaglia L, Nieto-García A, Otero-Romero S, Pappolla A, Rodriguez M, Sansano I, Río J, Tagliani P, Tur C, Vidal-Jordana Á, Vilaseca A, Villar A, Sastre-Garriga J, Oreja-Guevara C, Tintoré M, Montalban X, Arrambide G
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies
Mult Scler. 2024 Dec;30(14):1788-1801
DOI: 10.1177/13524585241297038
IF: 4.8
Cobo-Calvo Á, Gómez-Ballesteros R, Orviz A, Díaz Sánchez M, Boyero S, Aguado-Valcarcel M, Sepúlveda M, Rebollo P, López-Laiz P, Maurino J, Téllez Lara N
Therapeutic inertia in the management of neuromyelitis optica spectrum disorder
Front Neurol. 2024 Feb 21;15:1341473
DOI: 10.3389/fneur.2024.1341473
IF: 2.7
Selected Projects
PI21/01860: Unveiling the mechanisms leading to irreversible accumulation of disability in multiple sclerosis through quantitative multi-modal Magnetic Resonance Imaging
Principal Investigator: Carmen Tur Gómez
Agency: Instituto de Salud Carlos III (ISCIII)
Funding: 150,040 €
Period: 2022-2024
PI22/00750: Development of a global model of functional and structural reserve of the central nervous system in multiple sclerosis – ResEM Project
Principal Investigator: Jaume Sastre Garriaga
Agency: Instituto de Salud Carlos III (ISCIII)
Funding: 157,300 €
Period: 2023-2025
HORIZON. BEHIND-MS - 101137235 - GAP-101137235. Bridging EBV-Host ImbalaNce to Disease Onset and Progression in Multiple Sclerosis.
Principal Investigator: Manuel Comabella López
Agency: European Commission
Funding: 248,720 €
Period: 2023-2028
PI22/01570: Profiling of patients with highly active multiple sclerosis and assessment of highly efficacious treatment effects on the evolution of the disease
Principal Investigator: Georgina Arrambide
Agency: Instituto de Salud Carlos III (ISCIII)
Funding: 169,400 €
Period: 2023-2025
CPP2021-008475: Valorización de una terapia antígeno-específica para el tratamiento disruptivo de la diabetes tipo 1; esclerosis múltiple, miastenia gravis, enfermedad celíaca y artritis reumatoide
Principal Investigator: Carmen Espejo Ruiz
Agency: Ministerio de Ciencia e Innovación
Funding: 217,313.90 €
Period: 2022 - 2025
Patents
Compound for the treatment of autoimmune disease
Priority Number: EP24382257.4
Priority Date: 11/03/2024
Applicants: Peptomyc, SL; Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca; Fundació Privada Institut d'Investigació Oncològica de Vall Hebron; Institució Catalana de Recerca i Estudis Avançats.
Selected Dissemination Activities
Intel·ligència artificial en esclerosi múltiple. Lecture session presented at: Dia Mundial de l'EM. Organized by Fundació Esclerosi Múltiple (FEM), Centre d'Esclerosi Múltiple de Catalunya (CEMCAT) and Hospital Universitari de la Vall d'Hebron (HUVH)
Place: Barcelona, Spain
Date: 01/01/1970
Brief: On World MS Day 2024, Dr. C. Tur from the Clinical Neuroimmunology Group – Cemcat at Vall d’Hebron Research Institute (VHIR) delivered a lecture on the application of artificial intelligence in multiple sclerosis. The event was organized by the Multiple Sclerosis Foundation (FEM) and focused on the importance of early diagnosis.
MORE INFO
Presentació de l’eina. Informative Session presented at: Presentació de l’eina Decisions Compartides en Esclerosi múltiple. Organized by Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS).
Place: Barcelona, Spain
Date: 09/10/2024
Brief: Dr. Jaume Sastre-Garriga, from the Clinical Neuroimmunology Group – Cemcat at Vall d’Hebron Research Institute (VHIR), took part in the presentation of the “Shared Decisions in Multiple Sclerosis” tool. The event, organized by the Catalan Agency for Health Quality and Evaluation (AQuAS), promoted patient-centered care in MS.
MORE INFO
Sessions informatives en Esclerosi Múltiple. Organized by Centre d'Esclerosi Múltiple de Catalunya (CEMCAT)
Place: Cemcat. Barelona, Spain
Date: 01/01/1970
Brief: Description: One-hour informational sessions on topics that raise concerns among people with multiple sclerosis (MS) as well as their families and caregivers. These sessions feature the participation of leading researchers from the Clinical Neuroimmunology Research Group – Cemcat at Vall d’Hebron Research Institute (VHIR).
General objectives: These sessions aim to address the issues that most concern patients, family members, caregivers, and non-experts who are interested in gaining a better understanding of multiple sclerosis.
MORE INFO
Esclerosi Múltiple. La Revolució de la Recerca. Lecture session presented at: 8a Jornada de l'Associació d'Esclerosi Múltiple de la Comarca de l'Anoia. Organized by Associació Esclerosi Múltiple Anoia (AEMA).
Place: Igualada, Spain
Date: 01/01/1970
Brief: Dr. Xavier Montalban, from the Clinical Neuroimmunology Group – Cemcat at Vall d’Hebron Research Institute (VHIR), delivered a keynote lecture titled “Multiple Sclerosis: The Research Revolution”. The talk was part of the 8th Annual Meeting of the Anoia Multiple Sclerosis Association (AEMA), held in Igualada.
Dentro de diez años, la Esclerosis Múltiple estará 'controlada' en la mayoría de pacientes. Interview session presented at: Encuentro de Investigación del Proyecto M1. Organized by Asociación Esclerosis Múltiple España (EME).
Place: Madrid, Spain
Date: 05/08/2024
Brief: Dr. Xavier Montalban, from the Clinical Neuroimmunology Group – Cemcat at Vall d’Hebron Research Institute (VHIR), participated in an interview during the M1 Research Project Meeting. Organized by the Spanish Multiple Sclerosis Association (EME), the event focused on future prospects of MS management and control.
MORE INFO
